nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

20.02.2018 | Original Article – Cancer Research

NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma

verfasst von: Tomonori Sasahira, Yukiko Nishiguchi, Miyako Kurihara-Shimomura, Chie Nakashima, Hiroki Kuniyasu, Tadaaki Kirita

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In our previous global gene expression analysis, we identified NIPA-like domain containing 1 (NIPAL1), which encodes a magnesium transporter, as one of the most overexpressed genes in recurrent oral squamous cell carcinoma (OSCC). Although has been NIPAL1 linked with gout pathogenesis, little is known about its expression and function in human malignancies.

Methods

In this study, we examined NIPAL1 expression in 192 cases of OSCC by immunohistochemistry and performed a functional analysis of human OSCC cells.

Results

NIPAL1 immunostaining was observed in 39 of 192 OSCC patients (20.3%). NIPAL1 expression correlated significantly with cancer cell intravsation (P = 0.0062), as well as with poorer disease-free survival in a Kaplan–Meier analysis (P < 0.0001). Moreover, a multivariate Cox proportional hazards model analysis revealed that NIPAL1 expression was an independent predictor of disease-free survival in OSCC (P < 0.0001). In a functional analysis, NIPAL1 regulated the growth and adhesion of OSCC tumor cells and endothelial cells.

Conclusions

Our findings suggest that NIPAL1 might be a novel factor promoting OSCC tumorigenesis, as well as a useful molecular marker of OSCC.

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed

Birner P, Obermair A, Schindl M, Kowalski H, Breitenecker G, Oberhuber G (2001) Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 7:93–97PubMed

Bjorge T et al (2010) Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project Cancer. Epidemiol Biomark Prev 19:1737–1745. https://doi.org/10.1158/1055-9965.Epi-10-0230 CrossRef

Donnem T et al (2007) Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 13:6649–6657. https://doi.org/10.1158/1078-0432.ccr-07-0414 CrossRefPubMed

Fife CM et al (2017) Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration. Oncogene 36:501–511. https://doi.org/10.1038/onc.2016.220 CrossRefPubMed

Gao SL, Kong CZ, Zhang Z, Li ZL, Bi JB, Liu XK (2017) TRPM7 is overexpressed in bladder cancer and promotes proliferation, migration, invasion and tumor growth. Oncol Rep 38:1967–1976. https://doi.org/10.3892/or.2017.5883 CrossRefPubMedPubMedCentral

Goytain A, Hines RM, Quamme GA (2008) Functional characterization of NIPA2, a selective Mg2+ transporter. Am J Physiol Cell Physiol 295:C944–C953. https://doi.org/10.1152/ajpcell.00091.2008 CrossRef

Hammarsten J, Damber JE, Peeker R, Mellstrom D, Hogstedt B (2010) A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiol 34:574–579. https://doi.org/10.1016/j.canep.2010.06.014 CrossRefPubMed

Hardy S et al (2015) The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis. Oncogene 34:986–995. https://doi.org/10.1038/onc.2014.33 CrossRefPubMed

Kostantin E et al (2016) Inhibition of PRL-2.CNNM3 protein complex formation decreases breast cancer proliferation and tumor growth. J Biol Chem 291:10716–10725. https://doi.org/10.1074/jbc.M115.705863 CrossRefPubMedPubMedCentral

Kowalski LP, Carvalho AL, Martins Priante AV, Magrin J (2005) Predictive factors for distant metastasis from oral and oropharyngeal squamous cell carcinoma. Oral Oncol 41:534–541. https://doi.org/10.1016/j.oraloncology.2005.01.012 CrossRefPubMed

Kurihara M et al (2013) Protumoral roles of melanoma inhibitory activity 2 in oral squamous cell carcinoma. Br J Cancer 108:1460–1469. https://doi.org/10.1038/bjc.2013.27 CrossRefPubMedPubMedCentral

McBride SM, Busse PM, Clark JR, Wirth LJ, Ancukiewicz M, Chan AW (2014) Long-term survival after distant metastasis in patients with oropharyngeal cancer. Oral Oncol 50:208–212. https://doi.org/10.1016/j.oraloncology.2013.10.020 CrossRefPubMed

Middelbeek J et al (2012) TRPM7 is required for breast tumor cell metastasis. Cancer Res 72:4250–4261. https://doi.org/10.1158/0008-5472.Can-11-3863 CrossRefPubMed

Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S (1989) Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 18:391–395CrossRefPubMed

Nakayama A et al (2017) GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis 76:869–877. https://doi.org/10.1136/annrheumdis-2016-209632 CrossRefPubMed

Nomiya T, Nemoto K, Nakata E, Takai Y, Yamada S (2006) Expression of thymidine phosphorylase and VEGF in esophageal squamous cell carcinoma. Oncol Rep 15:1497–1501PubMed

Ren ZH, Zhang CP, Ji T (2016) Expression of SOX2 in oral squamous cell carcinoma and the association with lymph node metastasis. Oncol Lett 11:1973–1979. https://doi.org/10.3892/ol.2016.4207 CrossRefPubMedPubMedCentral

Reuter CW, Morgan MA, Eckardt A (2007) Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96:408–416. https://doi.org/10.1038/sj.bjc.6603566 CrossRefPubMedPubMedCentral

Sakamoto Y, Matsushita Y, Yamada S, Yanamoto S, Shiraishi T, Asahina I, Umeda M (2016) Risk factors of distant metastasis in patients with squamous cell carcinoma of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol 121:474–480. https://doi.org/10.1016/j.oooo.2015.11.022 CrossRefPubMed

Sasahira T et al (2008) High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 99:1806–1812. https://doi.org/10.1111/j.1349-7006.2008.00894.x PubMed

Sasahira T, Kirita T, Kurihara M, Yamamoto K, Bhawal UK, Bosserhoff AK, Kuniyasu H (2010) MIA-dependent angiogenesis and lymphangiogenesis are closely associated with progression, nodal metastasis and poor prognosis in tongue squamous cell carcinoma. Eur J Cancer 46:2285–2294. https://doi.org/10.1016/j.ejca.2010.04.027 CrossRefPubMed

Sasahira T et al (2014a) Transport and Golgi organisation protein 1 is a novel tumour progressive factor in oral squamous cell carcinoma. Eur J Cancer 50:2142–2151. https://doi.org/10.1016/j.ejca.2014.05.006 CrossRefPubMed

Sasahira T et al (2014b) HuD promotes progression of oral squamous cell carcinoma. Pathobiology 81:206–214. https://doi.org/10.1159/000366022 CrossRefPubMed

Sasahira T, Kurihara M, Nakashima C, Kirita T, Kuniyasu H (2016a) LEM domain containing 1 promotes oral squamous cell carcinoma invasion and endothelial transmigration. Br J Cancer 115:52–58. https://doi.org/10.1038/bjc.2016.167 CrossRefPubMedPubMedCentral

Sasahira T, Kurihara M, Nishiguchi Y, Fujiwara R, Kirita T, Kuniyasu H (2016b) NEDD 4 binding protein 2-like 1 promotes cancer cell invasion in oral squamous cell carcinoma. Virchows Arch 469:163–172. https://doi.org/10.1007/s00428-016-1955-4 CrossRefPubMed

Sasahira T, Nishiguchi Y, Fujiwara R, Kurihara M, Kirita T, Bosserhoff AK, Kuniyasu H (2016c) Storkhead box 2 and melanoma inhibitory activity promote oral squamous cell carcinoma progression. Oncotarget 7:26751–26764. https://doi.org/10.18632/oncotarget.8495 PubMedPubMedCentral

Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Stantic M et al (2015) TAp73 suppresses tumor angiogenesis through repression of proangiogenic cytokines and HIF-1alpha activity. Proc Natl Acad Sci USA 112:220–225. https://doi.org/10.1073/pnas.1421697112 CrossRefPubMed

Su PF, Huang WL, Wu HT, Wu CH, Liu TY, Kao SY (2010) p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner. Oral Oncol 46:734–739. https://doi.org/10.1016/j.oraloncology.2010.07.002 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Tremblay PL, Auger FA, Huot J (2006) Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK. MAP Kinases Oncogene 25:6563–6573. https://doi.org/10.1038/sj.onc.1209664 CrossRefPubMed

Wang J et al (2014) TRPM7 is required for ovarian cancer cell growth, migration and invasion. Biochem Biophys Res Commun 454:547–553. https://doi.org/10.1016/j.bbrc.2014.10.118 CrossRefPubMed

Wang W et al (2015) Increased risk of cancer in relation to gout: a review of three prospective cohort studies with 50,358 Subjects. Mediat Inflamm 2015:680853 https://doi.org/10.1155/2015/680853

Titel: NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma
verfasst von: Tomonori Sasahira
Yukiko Nishiguchi
Miyako Kurihara-Shimomura
Chie Nakashima
Hiroki Kuniyasu
Tadaaki Kirita
Publikationsdatum: 20.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2612-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Primary management of atypical meningioma: treatment patterns and survival outcomes by patient age

Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth

A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models

Management of elderly women with cervical cancer

Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma

Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie